Table 1 Characteristics of the population 65 years and older with a fragility fracture by gender
| Â | Women | Men | p-value |
|---|---|---|---|
Population 65 years in 2000 | 554,154 | 387,062 | - |
Number of fragility fractures (per 1000) | 19,813 (36 ‰) | 6039 (16 ‰) | < 0.0001 |
Average age in years (standard deviation) | 78.7 (7.7) | 76.6 (7.6) | < 0.0001 |
Age category in years (%) | Â | Â | < 0.0001 |
65–69 | 2842 (14.3) | 1289 (21.3) |  |
70–74 | 3581 (18.1) | 1326 (22.0) |  |
75–79 | 4312 (21.8) | 1333 (22.1) |  |
≥80 | 9078 (45.8) | 2091 (34.6) |  |
Site of fragility fracture (%) | Â | Â | < 0.0001 |
Vertebral | 3006 (15.2) | 1200 (19.9) | Â |
Wrist | 3391 (17.1) | 734 (12.2) | Â |
Hip | 9194 (46.4) | 2961 (49.0) | Â |
Humerus | 4222 (21.3) | 1144 (18.9) | Â |
Social status* (%) | Â | Â | < 0.0001 |
Living in a LTCF | 1303 (6.6) | 352 (5.8) | Â |
Living at home with maximum IS | 1840 (9.3) | 234 (3.9) | Â |
Living at home with partial IS | 8757 (44.2) | 2142 (35.5) | Â |
Living at home with no IS | 7913 (39.9) | 3311 (54.8) | Â |
Comorbidity index – mean (quartiles) | 7.2 (3, 6, 10) | 6.9 (2, 6, 10) | 0.0065 |
Prior BMD testing (%) | 1572 (7.9) | 100 (1.7) | < 0.0001 |
Prior OP treatment (%) | 3954 (20.0) | 247 (4.1) | < 0.0001 |
Long-term glucocorticoid use (%) | 407 (2.0) | 132 (2.2) | 0.5310 |
Average distance to nearest BMD device | 20.3 km | 23.4 km | < 0.0001 |
Median distance to nearest BMD device | 3.0 km | 3.5 km | < 0.0001 |
BMD testing 2 years after fracture (%) | 2594 (13.1) | 281 (4.6) | < 0.0001 |
OP treatment one year after fracture (%) | 5889 (29.7) | 596 (9.9) | < 0.0001 |
Death 2 years after fracture (%) | 4507 (22.8) | 2112 (35.0) | < 0.0001 |